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Introduction {#jcsm12264-sec-0005}
============

Chronic kidney disease (CKD) is among the leading causes of death worldwide including emerging giant economies such as India and China.[1](#jcsm12264-bib-0001){ref-type="ref"} Upon its development, kidney function deteriorates over time until it permanently fails. Management strategies have largely focused on slowing down progression to end‐stage renal disease (ESRD), at which time, patients are invariably expected to transition to renal replacement therapy, mostly in the form of maintenance dialysis treatment.[2](#jcsm12264-bib-0002){ref-type="ref"} Nevertheless, recent data suggest that attempts to delay or even prevent transition to dialysis therapy may not be inappropriate,[3](#jcsm12264-bib-0003){ref-type="ref"} including a 2009 study that showed that the initiation of dialysis was associated with a substantial and sustained decline in functional status of the elderly nursing home patients.[4](#jcsm12264-bib-0004){ref-type="ref"} Many patients with kidney disease prefer to opt to exhaust all conservative management options for CKD, including nutritional strategies, prior to considering dialysis therapy.[5](#jcsm12264-bib-0005){ref-type="ref"}

Century‐old evidence suggests that lower dietary protein intake may help with CKD management including slowing its progression, improving albuminuria, and controlling uraemia.[6](#jcsm12264-bib-0006){ref-type="ref"}, [7](#jcsm12264-bib-0007){ref-type="ref"}, [8](#jcsm12264-bib-0008){ref-type="ref"}, [9](#jcsm12264-bib-0009){ref-type="ref"} However, results from the *Modification of Diet in Renal Disease* study in 1994 were inconclusive with regards to the efficacy of a low‐protein diet (LPD) in slowing the rate of CKD progression.[10](#jcsm12264-bib-0010){ref-type="ref"} Several meta‐analyses that focused on the rate of CKD progression showed favourable but modest effects of an LPD.[11](#jcsm12264-bib-0011){ref-type="ref"}, [12](#jcsm12264-bib-0012){ref-type="ref"} Nevertheless, no single study has examined all clinically relevant outcomes, and fewer studies have focused on the role of an LPD in managing uraemia or other CKD complications such as mineral and bone disorders and metabolic acidosis without causing protein‐energy wasting or cachexia.[13](#jcsm12264-bib-0013){ref-type="ref"}

Protein‐energy wasting characterized by a decline in body protein mass and energy reserves, including muscle and fat wasting and visceral protein pool contraction, is an underappreciated condition in early to moderate stages of CKD and a strong predictor of adverse outcomes.[14](#jcsm12264-bib-0014){ref-type="ref"} The applicability of many nutritional interventions and their effects on outcomes in patients with moderate to advanced CKD, including those with protein‐energy wasting or at high risk of its development, has not been well studied. The challenge remains as to how to reconcile low dietary protein intake---to avoid or delay dialysis initiation---with adequate nutrient intake and nutritional therapy while insuring favourable nutritional status and to avoid or correct protein‐energy wasting.[13](#jcsm12264-bib-0013){ref-type="ref"} The field lacks an up‐to‐date systematic review and meta‐analysis study on the subject with a focus on the conservative management of CKD. There is an urgency to revisit all traditional and novel options for the non‐dialytic management of patients with advanced CKD. Given these considerations and given commonalities and distinctions of the old and emerging controlled trials over the past two decades following the Modification of Diet in Renal Disease study, we aimed to conduct a comprehensive systematic review and meta‐analysis study examining the effect of an LPD on the clinical management of patients with CKD.

Materials and methods {#jcsm12264-sec-0006}
=====================

K.K.‐Z., supported by other coauthors, searched MEDLINE (PubMed) and other relevant sources with no limitation in study type, language, and geographical area using the search terms including 'low protein diet', 'CKD', and 'clinical trial' as well as additional records identified through other sources including prior reviews. A field expert (K. K.‐Z) identified any additional relevant studies. The studies were included if they described data from controlled trials (including randomized, self‐controlled, parallel, and crossover trials) on CKD patients (excluding prevalent ESRD patients and those receiving dialysis treatment) to compare clinical outcomes across various protein intake levels (i.e. protein‐free, very‐low‐protein, low‐protein, moderate‐protein, high‐protein, very‐high‐protein, or unrestricted protein diets) or to compare a restricted protein intake with another intervention. An LPD was defined as a diet with a protein content of \<0.8 g/kg/day. To ensure meaningful sample size in each study given our focus on the conservative management of CKD, we selected only controlled trials that included at least 30 participants to ensure selection of studies with adequate sample size and higher level of robustness[15](#jcsm12264-bib-0015){ref-type="ref"} (*Figure* [1](#jcsm12264-fig-0001){ref-type="fig"}). The aforementioned endeavour was undertaken to both provide a comprehensive roster of relevant randomized controlled trials of LPD for CKD management, which has become Suppor[ting Information, *Table* **S2**](#jcsm12264-supitem-0002){ref-type="supplementary-material"} of a recently published *New England Journal of Medicine* review article, titled, 'Nutritional Management of Chronic Kidney Disease' by Kalantar‐Zadeh and Fouque,[16](#jcsm12264-bib-0016){ref-type="ref"} and for an additional meta‐analysis project that is presented in this manuscript.

![Flow diagram of the study selection. See also Suppor[ting Information, *Table* **S2**](#jcsm12264-supitem-0002){ref-type="supplementary-material"} of the *New England Journal of Medicine* review article, titled, 'Nutritional Management of Chronic Kidney Disease' by Kalantar‐Zadeh and Fouque.[16](#jcsm12264-bib-0016){ref-type="ref"}](JCSM-9-235-g001){#jcsm12264-fig-0001}

We extracted and tabulated the main characteristics and findings of the included studies as well as comments on their methodological quality and clinical significance (*Table* [1](#jcsm12264-tbl-0001){ref-type="table-wrap"}). Also, we evaluated the risk of bias using the Cochrane Collaboration\'s tool for assessing risk of bias (*Table* [2](#jcsm12264-tbl-0002){ref-type="table-wrap"}). We examined the effects of an LPD or very‐low‐protein diet (VLPD) (with or without supplementation with ketoacids or amino acids) on various outcome measures in CKD patients. The corresponding authors of the studies with incomplete results were contacted in order to request further data.

###### 

Selected controlled trials (with \>30 participants) that have examined the effects of an LPD or VLPD, with or without supplementation with ketoacids or amino acids, on various outcome measures in chronic kidney disease patients

  Study (year)                                                                                          Participants                                                                               Dietary intervention                                                                      Outcomes                                                                     Follow‐Up time               Results                                                                                                                                                                                          Comment
  ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------
  LPD vs. HPD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Jiang *et al*.[17](#jcsm12264-bib-0017){ref-type="ref"}, [18](#jcsm12264-bib-0018){ref-type="ref"}    60 new ESRD pts on PD with RKF                                                             LPD vs. sLPD (LPD + ketoacids) vs. HPD                                                    RKF and nutritional markers on PD                                            12 months                    RKF stable in sLPD group but decreased in the LPD and HPD groups.                                                                                                                                No change from baseline on nutritional status in any of the groups during follow‐up.
  Cianciaruso *et al*.[19](#jcsm12264-bib-0019){ref-type="ref"}                                         423 pts with CKD 4--5                                                                      Two different DPI levels 0.55 (*n* = 212) vs. 0.80 g/kg/day (*n* = 211)                   CKD progression and changes in blood and urinary biomarkers                  18 months                    Reduced urinary excretion of urea, Na, phos in LPD. No differences in phos, albumin, PTH, bicarbonate. No changes in body composition.                                                           Estimated DPI in low vs. high groups was 0.72 vs. 0.92 g/kg/day (*P* \< 0.05). 9 vs. 13 pts in LPD vs. higher DPI stated dialysis.
  MDRD study 1 Klahr *et al*.[10](#jcsm12264-bib-0010){ref-type="ref"}                                  585 pts with CKD 3--4 (GFR 25--55 mL/min/1.73m^2^)                                         Usual protein diet (DPI 1.3 g/kg/day) vs. LPD (0.6 g/kg/day)                              CKD progression, blood pressure, proteinuria, nutrition                      27 months (mean follow‐up)   Projected mean GFR decline at 3 years did not differ significantly between the diet groups. Faster GFR decline in the first 4 months in the LPD group.                                           Two concurrent randomized controlled trials. Serum albumin increased in both sVLPD and LPD groups and did not differ between groups.
  Locatelli *et al*.[20](#jcsm12264-bib-0020){ref-type="ref"}                                           456 pts with CKD 3--4                                                                      LPD (0.78 g/kg/day) vs. normal DPI (0.9 g/kg/day), both DEI \> 30 cal/kg/day              *Renal survival* defined as dialysis start or doubling of serum creatinine   2 years                      Borderline difference, slightly fewer pts assigned to LPD group reached the endpoint (*P* = 0.059).                                                                                              Substantial overlap in DPI between two groups.
  Williams *et al*.[21](#jcsm12264-bib-0021){ref-type="ref"}                                            95 pts with CKD 4--5                                                                       LPD (0.7 g/kg/day) vs. normal diet (DPI 1.02 and 1.14 g/kg/day) and varied phos content   CKD progression rates across three groups                                    18 months                    No differences in the reduction in creatinine clearance, dialysis initiation, or mortality among three groups.                                                                                   Minor weight loss in LPD.
  Ihle *et al*.[22](#jcsm12264-bib-0022){ref-type="ref"}                                                72 pts with CKD 4--5                                                                       LPD (0.6 g/kg/day) vs.higher DPI (0.8 g/kg/day)                                           GFR every 6 months                                                           18 months                    Stable GFR in LPD vs. loss of GFR in control group (*P* \< 0.05).                                                                                                                                LPD pts lost weight but no change in anthropometric measures or serum albumin.
  Rosman *et al*.[23](#jcsm12264-bib-0023){ref-type="ref"}, [24](#jcsm12264-bib-0024){ref-type="ref"}   247 pts with CKD 3--5                                                                      0.90--0.95 (CKD 3) vs. 0.70--0.80 g/kg/day (CKD 4--5) vs. unrestricted DPI                GFR after 2 or 4 years                                                       4 years                      After 2 years significant slowing of CKD progression in LPD but only in male pts.                                                                                                                4 year renal survival improvement in LPD (60 vs. 30%, *P* \< 0.025). PKD pts did not respond to LPD.
  VLPD vs. LPD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Garneata *et al*.[25](#jcsm12264-bib-0025){ref-type="ref"}                                            207 non‐diabetic pts with CKD 4--5 (eGFR \<30 mL/min/1.73m^2^) and proteinuria \<1 g/day   LPD (0.6 g/kg/day) vs. sVLPD (vegetarian VLPD 0.3 g/kg/day with KA)                       Dialysis initiation or 50% reduction in initial eGFR                         15 months                    Adjusted NNT (95% CI) to avoid dialysis was 22.4 (21.5--25.1) for pts with eGFR \< 30 mL/min/1.73m^2^ but decreased to 2.7 (2.6--3.1) for pts with eGFR \< 20 mL/min/1.73m^2^ in ITT analysis.   Correction of metabolic abnormalities occurred only with sVLPD. Compliance to diet was good, with no changes in nutritional measure.
  Mircescu *et al*.[26](#jcsm12264-bib-0026){ref-type="ref"}                                            53 non‐diabetic CKD 4--5 pts (eGFR \< 30 mL/min/1.73m^2^)                                  sVLPD (0.3 g/kg/day vegetable proteins) suppl. with KA vs. LPD                            Transition to dialysis, eGFR, and laboratory markers                         48 weeks                     Less dialysis initiation with sVLPD (4 vs. 27%). Stable eGFR in sVLPD but decreased eGFR in controls.                                                                                            Open‐label randomized, controlled trial. Higher bicarbonate and lower phos in sVLPD group.
  Prakash *et al*.[27](#jcsm12264-bib-0027){ref-type="ref"}                                             34 CKD pts (mean eGFR 28 mL/min/1.73m^2^)                                                  LPD (0.6 g/kg/day) with placebo vs. sVLPD (0.3 g/kg/day with KA)                          Changes in GFR and nutritional markers                                       9 months                     Stable GFR in the sVLPD vs. worsening nutritional measures and faster GFR decline in LPD group.                                                                                                  Prospective, randomized, double‐blind, placebo‐controlled single centre trial.
  Malvy *et al*.[28](#jcsm12264-bib-0028){ref-type="ref"}                                               50 pts with CKD 4--5 (eGFR \< 20 mL/min/1.73m^2^)                                          sVLPD (0.3 g/kg/day) with KA vs. LPD (0.65 g/kg/day)                                      3 mo to eGFR \>5 mL/min/1.73m^2^ or need for dialysis                        3 years                      SUN, lean body mass, and fat mass decreased in sVLPD group.                                                                                                                                      Randomized trial. No difference in renal survival, sVLPD pts lost 2.7 kg (both fat and lean body mass).
  Montes‐Delgado *et al*.[29](#jcsm12264-bib-0029){ref-type="ref"}                                      33 pts with CKD 3--5                                                                       LPD vs. LPD suppl. with a low‐protein and hypercaloric supplement                         Renal function and nutritional status                                        6 months                     Slower CKD progression in the supplemented group, with better nutritional status and higher adherence.                                                                                           22 patients completed the full 6 month study.
  MDRD study 2 Klahr *et al*.[10](#jcsm12264-bib-0010){ref-type="ref"}                                  255 pts with CKD 4--5 (GFR 13--24 mL/min/1.73m^2^)                                         LPD (0.6 g/kg/day) vs. sVLPD (0.3 g/kg/day with KA)                                       CKD progression, blood pressure, proteinuria, nutrition                      27 months (mean follow‐up)   sVLPD group had a marginally slower decline in GFR than LPD group (*P* = 0.067). Higher Ca, lower phos, alkaline phosphorus, and PTH levels in sVLPD group.                                      Two concurrent randomized controlled trials. Serum albumin increased in both sVLPD and LPD groups and did not differ between groups.
  Lindenau *et al*.[30](#jcsm12264-bib-0030){ref-type="ref"}                                            40 pts with CKD 5 (GFR \< 15 mL/min/1.73m^2^)                                              LPD with calcium suppl. (*n* = 18) vs. sVLPD (0.4 g/kg) with KA (*n* = 22)                Bone and mineral markers including via bone biopsies                         12 months                    Decreased serum phosphorus with sVLPD, improved markers of bone breakdown in bone biopsies in sVLPD group.                                                                                       CKD progression and other outcomes not assessed.
  VLPD or LPD vs. other interventions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Brunori *et al*.[31](#jcsm12264-bib-0031){ref-type="ref"}                                             56 non‐diabetic pts (\>70 yrs old) CKD 5 (GFR 5--7 mL/min/1.73m^2^)                        sVLPD (DPI: 0.3 g/kg/day, DEI: 35 Cal/kg/day) with KA, vs. dialysis initiation            Survival, hospitalization, and metabolic markers.                            Median time 26.5 months      Similar survival in both groups. Patients assigned to dialysis had a 50% higher degree of hospitalization.                                                                                       There was a continuous benefit of LPD over time.
  Teplan *et al*.[32](#jcsm12264-bib-0032){ref-type="ref"}                                              105 CKD pts (GFR 22--36 mL/min/1.73m^2^)                                                   LPD with KA and EPO vs. LPD without KA (with/without EPO)                                 CKD progression rate and nutritional measures                                3 years                      sLPD with KA/EPO showed slower CKD progression and increased leucine, isoleucine, valine and mild decrease in proteinuria (*P* \< 0.01).                                                         Role of EPO remained unclear.

AA, amino acid; AGE, advanced glycation end products; CKD, chronic kidney disease; DEI, dietary energy intake; DPI, dietary protein intake; eGFR, estimated glomerular filtration rate; EPO, recombinant human erythropoietin; EAA, essential amino acids; ESRD, end‐stage renal disease; HPD, high‐protein diet; ITT, intention to treat; KA, ketoacids supplement; LPD, low‐protein diet; NNT, number needed to treat; PEW, protein‐energy wasting; phos, phosphorus; PKD, polycystic kidney disease; pt, patient; pts, patients; sLPD, supplemented low‐protein diet; SUN, serum urea nitrogen; sVLPD, supplemented very‐low‐protein diet; VLPD, very‐low‐protein diet.

###### 

Risk of bias assessment in included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                        Random sequence generation?   Allocation concealment?   Blinding of participants?[a](#jcsm12264-note-0003){ref-type="fn"}   Blinding of outcome assessors?   Complete outcome data?   No selective reporting?
  ----------------------------------------------------------------------------------------------------- ----------------------------- ------------------------- ------------------------------------------------------------------- -------------------------------- ------------------------ -------------------------
  LPD vs. higher PD                                                                                                                                                                                                                                                                           

  Jiang *et al*.[17](#jcsm12264-bib-0017){ref-type="ref"}, [18](#jcsm12264-bib-0018){ref-type="ref"}    Unclear                       Unclear                   Unclear                                                             Unclear                          Yes                      Yes

  Cianciaruso *et al*.[19](#jcsm12264-bib-0019){ref-type="ref"}                                         Yes                           Yes                       Unclear                                                             Unclear                          Yes                      Yes

  MDRD study 1\                                                                                         Yes                           Unclear                   Unclear                                                             Unclear                          Yes                      Yes
  Klahr *et al*.[10](#jcsm12264-bib-0010){ref-type="ref"}                                                                                                                                                                                                                                     

  Locatelli *et al*.[20](#jcsm12264-bib-0020){ref-type="ref"}                                           Yes                           Yes                       Unclear                                                             Unclear                          Yes                      Yes

  Williams *et al*.[21](#jcsm12264-bib-0021){ref-type="ref"}                                            Yes                           Unclear                   Unclear                                                             Unclear                          Yes                      Yes

  Ihle *et al*.[22](#jcsm12264-bib-0022){ref-type="ref"}                                                Yes                           Unclear                   Unclear                                                             Unclear                          Yes                      Yes

  Rosman *et al*.[23](#jcsm12264-bib-0023){ref-type="ref"}, [24](#jcsm12264-bib-0024){ref-type="ref"}   Unclear                       Unclear                   No                                                                  No                               Yes                      Yes

  VLPD vs. LPD                                                                                                                                                                                                                                                                                

  Garneata *et al*.[25](#jcsm12264-bib-0025){ref-type="ref"}                                            Yes                           Unclear                   Unclear                                                             Unclear                          Yes                      Yes

  Mircescu *et al*.[26](#jcsm12264-bib-0026){ref-type="ref"}                                            Yes                           Unclear                   Unclear                                                             Unclear                          Yes                      Yes

  Prakash *et al*.[27](#jcsm12264-bib-0027){ref-type="ref"}                                             Yes                           Unclear                   Yes                                                                 Yes                              Yes                      Yes

  Malvy *et al*.[28](#jcsm12264-bib-0028){ref-type="ref"}                                               Unclear                       Unclear                   Unclear                                                             Unclear                          Yes                      Yes

  Montes‐Delgado *et al*.[29](#jcsm12264-bib-0029){ref-type="ref"}                                      Unclear                       Unclear                   Unclear                                                             Unclear                          Unclear                  Yes

  MDRD study 2\                                                                                         Yes                           Unclear                   Unclear                                                             Unclear                          Yes                      Yes
  Klahr *et al*.[10](#jcsm12264-bib-0010){ref-type="ref"}                                                                                                                                                                                                                                     

  Lindenau *et al*.[30](#jcsm12264-bib-0030){ref-type="ref"}                                            Unclear                       Unclear                   Unclear                                                             Unclear                          No                       Unclear

  V/LPD vs. other                                                                                                                                                                                                                                                                             

  Brunori *et al*.[31](#jcsm12264-bib-0031){ref-type="ref"}                                             Yes                           Yes                       No                                                                  No                               Yes                      Yes

  Teplan *et al*.[32](#jcsm12264-bib-0032){ref-type="ref"}                                              Unclear                       Unclear                   Unclear                                                             Unclear                          Unclear                  Yes
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Blinding of participants in diet‐based interventions is very difficult and almost unattainable.

Studies with clinical homogeneity (e.g. similar patients, interventions, and outcomes) were included in meta‐analyses. Statistical heterogeneity was assessed using the *I* ^2^ statistic. Summary estimates with a corresponding *I* ^2^ ≤ 50% were pooled using fixed‐effects meta‐analysis while those with a corresponding *I* ^2^ \> 50% were pooled using the random‐effects model. In addition, in order to ascertain that our results were not dependent on the selected summary estimate or meta‐analysis model, we completed sensitivity analyses. Statistical significance was defined as a 95% confidence interval with no overlap with the null effect value (risk difference/mean difference = 0). For statistical procedures, we used Stata 12 (StataCorp., College Station, TX, USA).

Results {#jcsm12264-sec-0007}
=======

Sixteen randomized controlled trials, reported in 17 articles, each with at least 30 participants, were included in our review (*Table* [1](#jcsm12264-tbl-0001){ref-type="table-wrap"}). Based on the interventions and comparisons, the included studies were divided into the following groups: (i) those comparing LPD with higher‐protein diets[10](#jcsm12264-bib-0010){ref-type="ref"}, [17](#jcsm12264-bib-0017){ref-type="ref"}, [18](#jcsm12264-bib-0018){ref-type="ref"}, [19](#jcsm12264-bib-0019){ref-type="ref"}, [20](#jcsm12264-bib-0020){ref-type="ref"}, [21](#jcsm12264-bib-0021){ref-type="ref"}, [22](#jcsm12264-bib-0022){ref-type="ref"}, [23](#jcsm12264-bib-0023){ref-type="ref"}, [24](#jcsm12264-bib-0024){ref-type="ref"}; (ii) those comparing VLPD with LPD[10](#jcsm12264-bib-0010){ref-type="ref"}, [25](#jcsm12264-bib-0025){ref-type="ref"}, [26](#jcsm12264-bib-0026){ref-type="ref"}, [27](#jcsm12264-bib-0027){ref-type="ref"}, [28](#jcsm12264-bib-0028){ref-type="ref"}, [29](#jcsm12264-bib-0029){ref-type="ref"}, [30](#jcsm12264-bib-0030){ref-type="ref"}; and (iii) those involving other comparisons[31](#jcsm12264-bib-0031){ref-type="ref"}, [32](#jcsm12264-bib-0032){ref-type="ref"} (*Table* [1](#jcsm12264-tbl-0001){ref-type="table-wrap"}). As all studies were not similar in their recruited patients and/or outcome measures, not all studies in each category were meta‐analysed (*Figures* [2](#jcsm12264-fig-0002){ref-type="fig"} and [3](#jcsm12264-fig-0003){ref-type="fig"}).

![Low‐protein diets (LPD: \<0.8 g/kg/day) vs. higher‐protein diets (HPD: \>0.8 g/kg/day). (A) Risk of progression to end‐stage renal disease was 4% lower in those who received low‐protein diets. (B) The pooled results showed a trend towards a lower risk of all‐cause death in those who received low‐protein diets; however, the trend was not significant. (C) On average, 12 month serum bicarbonate was 1.46 mEq/L higher in those who received low‐protein diets. (D) The pooled results indicated that 12 month serum phosphorus (in mg/dL) was comparable. The 'Overall' shows the results of the heterogeneity test (in all forest plots). RD, risk difference aka absolute risk reduction. WMD, weighted mean difference.](JCSM-9-235-g002){#jcsm12264-fig-0002}

![Very‐low‐protein diets (VLPD: \<0.4 mg/kg/day) vs. low‐protein diets (LPD: 0.4--0.8 mg/kg/day). (A) Risk of progression to end‐stage renal disease was 13% lower in those who received very‐low‐protein diets. (B) The pooled results showed a trend towards lower glomerular filtration rate (GFR) decline (in mL/min/year) in those who received very‐low‐protein diets; however, the difference was not significant. The results were pooled using the random‐effects model because of the observed statistical heterogeneity. (C) On average, 1 year GFR was 3.95 mL/min/1.73m^2^ higher in those who received very‐low‐protein diets. (D) The pooled results indicated a trend towards lower 1 year serum urea (in mg/dL) in those who received very‐low‐protein diets. The results of Prakash[27](#jcsm12264-bib-0027){ref-type="ref"} were based on a follow‐up of 9 months. ES, estimate of effect (in this case: GFR decline).](JCSM-9-235-g003){#jcsm12264-fig-0003}

Low‐protein diet vs. higher‐protein diets {#jcsm12264-sec-0008}
-----------------------------------------

For this comparison, LPD was defined as a protein intake of \<0.8 mg/kg/day; therefore, VLPD was also considered a subgroup of LPD. Our pooled results showed that the risk of progression to ESRD was significantly lower in those who received LPD compared with those who received higher‐protein diets (*Figure* [2](#jcsm12264-fig-0002){ref-type="fig"}A). In addition, the pooled results indicated a trend towards lower all‐cause death in those who received LPD (*Figure* [2](#jcsm12264-fig-0002){ref-type="fig"}B).

We also meta‐analysed other metabolic factors, which showed that 1 year serum bicarbonate was significantly higher in those who received LPD (*Figure* [2](#jcsm12264-fig-0002){ref-type="fig"}C). However, 1 year serum phosphorus was comparable in the two groups (*Figure* [2](#jcsm12264-fig-0002){ref-type="fig"}D). We could not meta‐analyse results representing parathyroid hormone (PTH), calcium, and other metabolic factors because of their clinical and methodological heterogeneity.

In addition to the results of our meta‐analysis, some results by individual studies were also informative: serum PTH was not significantly different in the two intervention groups according to the results by Cianciaruso *et al*.[19](#jcsm12264-bib-0019){ref-type="ref"} and Ihle *et al*.[22](#jcsm12264-bib-0022){ref-type="ref"} However, Malvy *et al*.[28](#jcsm12264-bib-0028){ref-type="ref"} completed a longer follow‐up (up to 40 months) and revealed a significantly lower PTH in those who received a lower protein intake (mean PTH: 2.71 vs. 5.91 ng/mL; *P* \< 0.001). Similarly, serum calcium was not significantly different as reported by Ihle *et al*.[22](#jcsm12264-bib-0022){ref-type="ref"} and Rosman *et al*.[23](#jcsm12264-bib-0023){ref-type="ref"} However, it was significantly higher in the study by Malvy *et al*.[28](#jcsm12264-bib-0028){ref-type="ref"} with a longer follow‐up duration (serum calcium: 2.42 vs. 2.25 mmol/L; *P* \< 0.01).

Also, Jiang *et al*.[17](#jcsm12264-bib-0017){ref-type="ref"} showed that in peritoneal dialysis patients, those who received an LPD had better preservation of glomerular filtration rate (GFR) and residual kidney function. In addition, PTH was significantly lower in those who received ketoacid‐supplemented LPD. However, serum phosphorus and calcium were not significantly different between the two intervention groups.

Very‐low‐protein diet vs. low‐protein diet {#jcsm12264-sec-0009}
------------------------------------------

Although the primary aim of this review was to compare LPD with higher‐protein diets, we also performed meta‐analyses of studies comparing VLPD with LPD. The two dietary groups were respectively defined as those with protein intakes of \<0.4 and 0.4--0.8 mg/kg/day. The pooled results showed that the progression to ESRD was significantly lower (*Figure* [3](#jcsm12264-fig-0003){ref-type="fig"}A) and 1 year GFR was significantly higher (*Figure* [3](#jcsm12264-fig-0003){ref-type="fig"}C) in those who received VLPD compared with LPD. In addition, the pooled results revealed trends towards lower GFR decline (*Figure* [3](#jcsm12264-fig-0003){ref-type="fig"}B) and lower 1 year serum urea (*Figure* [3](#jcsm12264-fig-0003){ref-type="fig"}D) in those who received VLPD; however, the trends were not significant. The results representing bicarbonate, phosphorus, PTH, and calcium could not be meta‐analysed because of their heterogeneity.

Again, in addition to the results of our meta‐analysis, we summarize some key results from the individual studies: Garneata *et al*.[25](#jcsm12264-bib-0025){ref-type="ref"} observed higher serum bicarbonate (22.9 vs. 16.2 mEq/L, *P* \< 0.01), higher serum calcium (4.4 vs. 3.9 mmol/L, *P* \< 0.01), and lower serum phosphorus levels (4.4 vs. 6.2 mg/dL, *P* \< 0.01) in those who received VLPD vs. LPD. Similarly, Mircescu *et al*.[26](#jcsm12264-bib-0026){ref-type="ref"} showed higher serum bicarbonate (23.4 vs. 17.6 mg/dL), higher serum calcium (4.4 vs. 3.9 mmol/L), and lower phosphorus (4.5 vs. 6 mg/dL) in those who received VLPD compared with LPD.

Also, Lindenau *et al*.[30](#jcsm12264-bib-0030){ref-type="ref"} reported that in patients with advanced CKD, those who received VLPD showed better control of renal osteodystrophy markers including PTH (0.6 vs. 1.53 ng/mL), osteoid surface (34.3 vs. 51.9), and bone volume (27.9 vs. 25.2); however, most differences did not reach statistical significance.

Sensitivity analyses {#jcsm12264-sec-0010}
--------------------

The results of our sensitivity analyses were comparable with the main meta‐analyses, indicating that our results were not dependent upon the selected meta‐analysis methods (see [Supporting Information, *Figures* S1 and S2](#jcsm12264-supitem-0001){ref-type="supplementary-material"}).

Other comparisons {#jcsm12264-sec-0011}
-----------------

Two included studies[31](#jcsm12264-bib-0031){ref-type="ref"}, [32](#jcsm12264-bib-0032){ref-type="ref"} compared LPD/VLPD with other interventions: Brunori *et al*.[31](#jcsm12264-bib-0031){ref-type="ref"} completed a non‐inferiority trial of supplemented VLPD vs. dialysis in elderly ESRD patients without diabetes, and they observed that the survival was not higher in those who received VLPD. In the other study, Teplan *et al*.[32](#jcsm12264-bib-0032){ref-type="ref"} compared three interventions in CKD patients: (i) LPD supplemented with ketoacids plus human recombinant erythropoietin (EPO); (ii) non‐supplemented LPD plus EPO; and (iii) non‐supplemented LPD alone. They observed that patients receiving supplemented LPD plus EPO had lower GFR decline and proteinuria and better metabolic profile. None of the studied trials reported increased risk of protein‐energy wasting or cachexia despite lower protein intake. There was no safety issue noted in any of the trials.

Discussion {#jcsm12264-sec-0012}
==========

Upon meta‐analysing contemporary clinical trials of large sample size (\>30 participants in each trial) that have examined an LPD for the management of CKD, we found that in comparison with diets with protein intake of \>0.8 g/kg/day, diets with restricted protein intake (\<0.8 g/kg/day) were associated with higher serum bicarbonate levels, lower phosphorus levels, lower rates of progression to ESRD, and a trend towards lower rates of all‐cause death. In addition, VLPD (protein intake: \<0.4 g/kg/day) was associated with even greater preservation of kidney function and reduction in the rate of progression to ESRD. These data may have important clinical and public health implications upon the conservative management of CKD.

For over half a century, we have regarded dialysis therapy as a life‐saving intervention among patients with advanced kidney failure, in whom survival would otherwise be impossible. To that end, more dialysis and earlier dialysis initiation have been considered to more favourable patient care strategies, whereas delayed initiation or less frequent haemodialysis treatment (i.e. less than thrice‐weekly haemodialysis) has been discouraged. However, emerging studies in recent years have cast doubt on the universal superiority of earlier dialysis initiation and more frequent dialysis treatments in the management of advanced CKD. A study in 2009 suggested that among nursing home residents with advanced kidney disease, initiation of dialysis was associated with a substantial and sustained decline in functional status.[4](#jcsm12264-bib-0004){ref-type="ref"} A provocative clinical trial from Australia and New Zealand in 2010 suggested that planned early initiation of dialysis in patients with Stage 5 CKD was not associated with improved survival or other clinical outcomes.[3](#jcsm12264-bib-0003){ref-type="ref"} These data have been supported by an increasing number of observational studies across different dialysis populations.[33](#jcsm12264-bib-0033){ref-type="ref"} To that end, it is important to revisit the old adage of the nutritional management of CKD and re‐examine whether the use of LPD can be leveraged to conservatively manage uraemic symptoms without the need for dialysis initiation. This potential application of an LPD is beyond and above its traditional use in studies that have employed it to slow progression of kidney disease. Even though the latter is of immense clinical importance, many clinicians often encounter patients in very late stages of CKD, for example, estimated GFR \< 25 mL/min/1.73m^2^, who wish to avoid or defer dialysis therapy by any means possible. Several individual trials[17](#jcsm12264-bib-0017){ref-type="ref"}, [18](#jcsm12264-bib-0018){ref-type="ref"}, [22](#jcsm12264-bib-0022){ref-type="ref"}, [23](#jcsm12264-bib-0023){ref-type="ref"}, [24](#jcsm12264-bib-0024){ref-type="ref"}, [25](#jcsm12264-bib-0025){ref-type="ref"}, [26](#jcsm12264-bib-0026){ref-type="ref"}, [27](#jcsm12264-bib-0027){ref-type="ref"}, [28](#jcsm12264-bib-0028){ref-type="ref"}, [29](#jcsm12264-bib-0029){ref-type="ref"}, [30](#jcsm12264-bib-0030){ref-type="ref"}, [34](#jcsm12264-bib-0034){ref-type="ref"} as well as meta‐analysis studies[12](#jcsm12264-bib-0012){ref-type="ref"}, [35](#jcsm12264-bib-0035){ref-type="ref"}, [36](#jcsm12264-bib-0036){ref-type="ref"}, [37](#jcsm12264-bib-0037){ref-type="ref"} have shown the benefits of protein restriction for such conservative management of CKD patients.[38](#jcsm12264-bib-0038){ref-type="ref"}

We found that the risk of progression to ESRD was significantly lower in the LPD compared with higher‐protein diets and also found a trend towards greater survival in the former group. The 1 year serum bicarbonate level was significantly higher in those who received an LPD, which is an important metric in the treatment of CKD‐associated acidosis and its deleterious effects.[39](#jcsm12264-bib-0039){ref-type="ref"} We also found lower phosphorus levels and lower azotemia with an LPD, which are important targets for the conservative management of CKD without dialysis. The safety and adherence to an LPD was not inferior to a normal protein diet in individual studies. However, we could not meta‐analyse results representing PTH, calcium, and other selected metabolic factors because of the clinical and methodological heterogeneity of the clinical trials. However, these collective results suggest that an LPD may have a potential role in the conservative management of CKD.

As a systematic review and meta‐analysis study, our findings were limited by the available data regarding the role of restricted protein intake in the management of CKD patients. The included studies were heterogeneous in their interventions, and they did not report all relevant clinical outcomes. Also, because of our limited resources, we were unable to search other electronic databases beyond PubMed. Nevertheless, we were inclusive in our data synthesis and reported on the meta‐analyses of various clinical outcomes using the most up‐to‐date evidence, while we excluded studies with \<30 participants as our key a priori selection criterion to ensure that only well‐designed studies with adequate statistical powers are included. In addition, the external validity of our findings may be less certain, as the efficacy of the LPD in the controlled conditions of RCTs does not necessarily translate into its effectiveness if CKD patients are not adequately compliant to the LPD. Furthermore, we did not assess the risk of publication bias across our included studies because of the few studies pooled together in each meta‐analysis. In fact, tests of publication bias, for example, Egger or Begg & Mazumdarand may generate inaccurate or misleading results if their 'sample size', that is, the number of pooled studies, is small.

In conclusion, the current evidence confirms the effect of restricted dietary protein intake on favourable metabolic surrogates of kidney function including azotemia, bone and mineral disorder, and acidosis, as well as slower kidney function loss, slower progression of CKD, and lower rates of ESRD and death. None of the studied trials reported increased risk of protein‐energy wasting or cachexia despite lower protein intake, nor was there any safety issue in any of the trials. Future studies may focus on further examining the selection of appropriate patients for nutritional interventions and other approaches in the conservative management of patients with advanced CKD and investigating the role of adherence to such therapies.
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###### 

**Supplemental Figure S1A.** Risk of progression to end‐stage renal disease in low‐protein diet (≤0.6 g/kg/day) vs. higher‐protein diets (\>0.6 g/kg/day): **Using Random‐effects model.**

**Supplemental Figure S1B.** Risk of progression to end‐stage renal disease in low‐protein diet (≤0.6 g/kg/day) vs. higher‐protein diets (\>0.6 g/kg/day): **Using Relative Risk.**

**Supplemental Figure S1C.** Risk of all‐cause death in low‐protein diet (≤0.6 g/kg/day) vs. higher‐protein diets (\>0.6 g/kg/day): **Using Relative Risk.**

**Supplemental Figure S1D.** 12‐month serum bicarbonate (mEq/L) in low‐protein diet (≤0.6 g/kg/day) vs. higher‐protein diets (\>0.6 g/kg/day): **Using Standardized Mean Difference.**

**Supplemental Figure S1E.** 12‐month serum phosphorus (in mg/dl) in low‐protein diet (≤0.6 g/kg/day) vs. higher‐protein diets (\>0.6 g/kg/day): **Using Standardized Mean Difference.**

**Supplemental Figure S2A.** Risk of progression to end‐stage renal disease in very low protein diet (\<0.4 g/kg/day) vs. low protein diet (0.4--0.6 g/kg/day): **Using Relative Risk.**

**Supplemental Figure S2B.** 1‐year glomerular filtration rate decline (ml/min/1.73m^2^) in very low protein diet (\<0.4 g/kg/day) vs. LPD (0.4--0.6 g/kg/day): **Using Standardized Mean Difference (SMD).**

**Supplemental Figure S2C.** 1‐year serum urea (mg/dl) in VLPD (\<0.4 g/kg/day) vs. LPD (0.4--0.6 g/kg/day): **Using Standardized Mean Difference (SMD).**

###### 

Click here for additional data file.

###### 

**Supplementary Table S2.** Selected controlled trials (with greater than 30 participants) that have examined the effects of low‐protein or very low‐protein diets (with or without supplementation with ketoacids or amino‐acids) on various outcome measures in patients with chronic kidney disease.

###### 

Click here for additional data file.
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